Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced that co-founder Dr. Phillip A. Sharp will retire from the Board of Directors effective May 8, 2025. Dr. Sharp, a Nobel Prize laureate who helped pioneer the RNAi revolution, has served as a key advisor since co-founding the company in 2002.
Dr. Sharp will continue as a member of Alnylam's Scientific Advisory Board. His distinguished career includes winning the 1993 Nobel Prize in Physiology or Medicine for RNA splicing discovery, the 2004 National Medal of Science, and the 2020 AACR Award for Lifetime Achievement in Cancer Research. He serves as Institute Professor Emeritus at MIT's Koch Institute for Integrative Cancer Research and was Founding Director of the McGovern Institute for Brain Research.
Alnylam Pharmaceuticals (Nasdaq: ALNY) ha annunciato che il co-fondatore Dr. Phillip A. Sharp si ritirerà dal Consiglio di Amministrazione a partire dall'8 maggio 2025. Il Dr. Sharp, vincitore del Premio Nobel che ha contribuito a pionierare la rivoluzione dell'RNAi, ha svolto un ruolo chiave come consulente sin dalla fondazione dell'azienda nel 2002.
Il Dr. Sharp continuerà come membro del Consiglio Scientifico di Alnylam. La sua carriera distintiva include la vittoria del Premio Nobel per la Fisiologia o Medicina nel 1993 per la scoperta dello splicing dell'RNA, la Medaglia Nazionale della Scienza del 2004 e il Premio AACR per il Riconoscimento della Carriera nella Ricerca sul Cancro nel 2020. È Professore Emerito presso l'Istituto Koch del MIT per la Ricerca Integrativa sul Cancro ed è stato Direttore Fondatore dell'Istituto McGovern per la Ricerca sul Cervello.
Alnylam Pharmaceuticals (Nasdaq: ALNY) anunció que el cofundador Dr. Phillip A. Sharp se retirará de la Junta Directiva a partir del 8 de mayo de 2025. El Dr. Sharp, laureado con el Premio Nobel que ayudó a pionear la revolución del RNAi, ha sido un asesor clave desde la cofundación de la empresa en 2002.
El Dr. Sharp continuará como miembro del Consejo Asesor Científico de Alnylam. Su carrera distinguida incluye haber ganado el Premio Nobel de Fisiología o Medicina en 1993 por el descubrimiento del empalme de RNA, la Medalla Nacional de Ciencia de 2004 y el Premio AACR por Logros de por Vida en Investigación del Cáncer en 2020. Es Profesor Emérito en el Instituto Koch del MIT para la Investigación Integrativa del Cáncer y fue Director Fundador del Instituto McGovern para la Investigación del Cerebro.
알니람 제약 (Nasdaq: ALNY)은 공동 창립자 필립 A. 샤프 박사가 2025년 5월 8일부로 이사회에서 은퇴한다고 발표했습니다. 노벨상 수상자인 샤프 박사는 RNAi 혁명을 선도하는 데 기여했으며, 2002년 회사를 공동 설립한 이후 주요 자문 역할을 해왔습니다.
샤프 박사는 알니람의 과학 자문 위원회 멤버로 계속 활동할 것입니다. 그의 뛰어난 경력에는 1993년 RNA 스플라이싱 발견으로 생리학 또는 의학 분야에서 노벨상을 수상한 것, 2004년 국가 과학 메달 수상, 2020년 암 연구에 대한 평생 공로로 AACR 상을 수상한 것이 포함됩니다. 그는 MIT의 코흐 통합 암 연구소 명예 교수로 재직 중이며, 맥거번 뇌 연구소의 설립 이사였습니다.
Alnylam Pharmaceuticals (Nasdaq: ALNY) a annoncé que le cofondateur Dr. Phillip A. Sharp prendra sa retraite du conseil d'administration à compter du 8 mai 2025. Le Dr. Sharp, lauréat du prix Nobel qui a contribué à la révolution de l'ARNi, a été un conseiller clé depuis la cofondation de l'entreprise en 2002.
Le Dr. Sharp continuera en tant que membre du Conseil consultatif scientifique d'Alnylam. Sa carrière distinguée comprend le prix Nobel de physiologie ou médecine en 1993 pour la découverte de l'épissage de l'ARN, la Médaille nationale des sciences en 2004 et le prix AACR pour les réalisations de toute une vie en recherche sur le cancer en 2020. Il est professeur émérite à l'Institut Koch du MIT pour la recherche intégrative sur le cancer et a été directeur fondateur de l'Institut McGovern pour la recherche sur le cerveau.
Alnylam Pharmaceuticals (Nasdaq: ALNY) gab bekannt, dass der Mitbegründer Dr. Phillip A. Sharp am 8. Mai 2025 aus dem Vorstand zurücktreten wird. Dr. Sharp, Nobelpreisträger, der half, die RNAi-Revolution zu pionieren, war seit der Gründung des Unternehmens im Jahr 2002 ein wichtiger Berater.
Dr. Sharp wird weiterhin Mitglied des Wissenschaftlichen Beirats von Alnylam bleiben. Seine herausragende Karriere umfasst den Gewinn des Nobelpreises für Physiologie oder Medizin im Jahr 1993 für die Entdeckung des RNA-Spleißens, die National Medal of Science 2004 und den AACR Award for Lifetime Achievement in Cancer Research 2020. Er ist Emeritus Professor am Koch Institute for Integrative Cancer Research des MIT und war Gründungsdirektor des McGovern Institute for Brain Research.
- Orderly transition with continued Scientific Advisory Board involvement
- Maintains institutional knowledge through ongoing advisory role
- Loss of experienced board member and co-founder
“Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam’s founding and the development of a transformative new class of medicines,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “He has provided invaluable guidance over the past twenty-two years that has shaped the remarkable company we have built. On behalf of Alnylam – and in honor of the tens of thousands of patients worldwide who have benefitted from RNAi therapeutics – I want to thank Phil for his incredible vision and lasting impact on the field of medicine.”
“Phil has made so many important scientific discoveries and his role at Alnylam has been a critical one,” said Amy W. Schulman, Chair of the Alnylam Board of Directors. “The Board and I want to thank him – we are so grateful to Phil for his role in shaping not only Alnylam but also an entire industry.”
Dr. Sharp is a distinguished scientific leader who holds a multitude of positions and honors throughout academia and industry. He was awarded a Nobel Prize in Physiology or Medicine in 1993 for the discovery of RNA splicing. Additionally, he was awarded the 2004 National Medal of Science and the American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research in 2020. Dr. Sharp is an Institute Professor Emeritus of the Koch Institute for Integrative Cancer Research at MIT and the Founding Director of the McGovern Institute for Brain Research at MIT. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. In addition to co-founding Alnylam, Dr. Sharp also co-founded Biogen and has served as a director for numerous other biotechnology companies.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305875945/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When will Dr. Phillip Sharp retire from Alnylam's (ALNY) Board of Directors?
What role will Dr. Sharp maintain at Alnylam (ALNY) after his board retirement?
How long has Dr. Sharp been involved with Alnylam (ALNY)?
What major scientific achievements has Dr. Sharp accomplished during his career?
